# Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia

> **NCT01513109** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jules Bordet Institute** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myelogenous Leukemia
- Myeloid Leukemia in Remission
- Effects of Immunotherapy

## Interventions

- **BIOLOGICAL:** Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)

## Key facts

- **NCT ID:** NCT01513109
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513109, "Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01513109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*